Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature

Table 2

Percentage of common (>5%) cutaneous adverse events with dabrafenib treatment.

Adverse events	Percentage (%)
Actinic keratosis	10.7 [9]–66.7 [14]
Hyperkeratosis	27 [13]–39.4 [9]
Pruritus	5.35 [9]–33.3 [14]
Photosensitivity	2.67 [9]–33.3 [14]
Panniculitis	33.3 [14]
Keratosis pilaris	33.3 [14]
Alopecia	28.8 [9]
Skin papilloma	15 [13]–25.13 [9]
Palmar-plantar dysesthesia	20.32 [9]
Rash	18.72 [9]
Dry skin	10.7 [9]
Seborrheic keratosis	8.56 [9]
Hair texture abnormal	6.42 [9]
cSCC	1.6 [9]

cSCC: cutaneous squamous cell carcinoma.
Indicated numbers beside the percentages denote the related references.